XRTX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	38 548.00
Średni wolumen	51 514.00
Kapitalizacja rynkowa	47.85M
EPS	$0 ( 2024-03-31 )
Następna data zysków	( $0 ) 2024-06-27
Last Dividend	$0.0750 ( 2014-01-31 )
Next Dividend	$0 ( N/A )
P/E	-6.49
ATR14	$0.0640 (2.41%)

XORTX Therapeutics Inc. Korelacja

10 Najbardziej pozytywne korelacje
VTYX	0.922
ALXO	0.895
RCM	0.893
JRJC	0.878
FEMY	0.877
CTMX	0.876
QRTEA	0.875
GNTY	0.873
GOEV	0.872
NAKD	0.87

10 Najbardziej negatywne korelacje
IDCC	-0.895
OTEX	-0.892
VBOCU	-0.89
BLBD	-0.888
MPRA	-0.887
OVLY	-0.887
NVCN	-0.887
GPACU	-0.886
OVID	-0.886
GRBK	-0.885

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

XORTX Therapeutics Inc. Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.520

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

XORTX Therapeutics Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XORTX Therapeutics Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.0500	2011-08-10
Last Dividend	$0.0750	2014-01-31
Next Dividend	$0	N/A
Payout Date	2014-02-17
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$0.795	--
Avg. Dividend % Per Year	0.00%	--
Score	1.61	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.61

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-1.171	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.972	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.44	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	9.15	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00429	-1.500	9.93	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-5.22	2.00	-1.741	-3.48	[0 - 30]
freeCashFlowPerShareTTM	-5.25	2.00	-2.63	-5.25	[0 - 20]
debtEquityRatioTTM	0.00468	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-366.22	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.285

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.681	1.000	-0.170	0	[1 - 100]
returnOnEquityTTM	-0.972	2.50	-7.65	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-5.25	2.00	-1.751	-5.25	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-5.22	2.00	-1.741	-3.48	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0783	1.500	-2.81	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-2.39

XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.